AI Generation Serves as a Quality Control Instrument for Bioprocessing
Colin Zick, a partner at Foley Hoag, will speak at a town hall on AI and digital transformation in bioprocessing next week. Zick, an advocate for the use of AI in various industries, shares his insights on the potential and challenges of AI in the field of bioprocessing.
One of the classic issues with AIs, according to Zick, is the assumption that everything they produce is correct. He emphasizes the need for a process to verify the results, as the AI developed by his firm, despite its capabilities, has incorrectly stated details about his personal life, such as his children's names, the number of children he has, and his marital status.
However, Zick finds the application of AI for error checking in documents to be a win-win situation. The AI either finds no mistakes or mistakes that can be checked for, providing time savings. In fact, Zick notes that using the AI for error checking takes no time, while asking a colleague for the same task would take a significant amount of time.
The AI developed by Zick's firm can be used to find mistakes in documents that Zick has already written, potentially saving him time and serving as an extra pair of "eyes." Furthermore, the AI has been effective in managing large datasets in bioprocessing, as well as many other industries.
Zick believes that AI can be a valuable tool for considering legal issues as part of a process in projects or processes. He suggests including AI-generated analyses in quality assurance processes to improve results in new projects or processes.
The quality of the data being managed and used to feed the AI is important to consider, as per Zick. AIs are assisting with the management of large datasets in bioprocessing, but the accuracy of the AI's outputs depends on the quality of the data it is given.
Zick compares AIs to tools like hammers or shovels, stating that understanding their realities and risks is necessary to find opportunities. He believes that bioprocessing scientists, due to their culture of quality assurance and working with complex systems, have the opportunity to explore new applications for AI.
However, Zick cautions that generative AIs like ChatGPT have exciting, creative applications in bioprocessing, but their risks and benefits need to be thoroughly evaluated. The AI developed by Zick's firm has not been fed the data necessary to write a biography accurately, leading to inaccuracies. The opportunity cost of using a colleague for error checking is significant compared to using the AI, according to Zick.
The AI developed by Zick's firm does not have the ability to know what it doesn't know, leading to it trying to generate information regardless, resulting in a mishmash of associated information. This limitation is demonstrated by its errors in Zick's personal life details.
Despite these challenges, Zick believes that the opportunities offered by AI in bioprocessing are significant. He looks forward to discussing these opportunities and realities further at the town hall on AI and digital transformation in bioprocessing.
The speaker for the Townhall session on "AI & Digital Transformation in Bioprocessing-Opportunities versus Realities?" at the 17th Annual Bioprocessing Summit in Boston has not been specifically listed in the available search results.
